Key Takeaways
- • Bain Capital has signed final agreements to acquire 100% of Vitabiotics, the UK's leading nutraceutical company, at a valuation exceeding $1 billion (approximately £900 million to $1.2 billion across sources).
- • Bain emerged as the sole winner after rival private equity bidders EQT and TPG Capital exited the auction process, positioning this as a significant strategic acquisition in the fast-growing consumer healthcare sector.
- • Vitabiotics, founded by Indian-origin entrepreneur Dr. Kartar Lalvani, operates globally across the UK, China, and India under premium vitamin and supplement brands including Wellman, Wellwoman, Perfectil, Pregnacare, and Osteocare, exporting to over 100 countries.
- • The acquisition adds a proven consumer healthcare asset to Bain's portfolio, particularly strengthening its position in the nutraceuticals market following the successful close of its Asia Fund VI at $10.5 billion in total capital earlier in 2026.
- • The deal reflects accelerating dealmaking momentum in India's wellness and nutraceuticals sector, with competing acquisitions by USV Pharma, HUL, Warburg Pincus, and Goldman Sachs Private Equity signaling strong investor appetite for scaled health and wellness brands.
Summary
Bain Capital has signed definitive agreements to acquire a controlling stake in Vitabiotics Ltd., the UK's largest vitamin and supplement manufacturer, in a transaction valued at more than $1 billion. The private equity firm secured full ownership of the nutraceuticals company after emerging as the frontrunner from a competitive bidding process that initially included rival bidders EQT and TPG Capital, both of whom withdrew from the auction. An official announcement of the transaction is expected imminently.
Vitabiotics, founded by Indian-origin entrepreneur Dr. Kartar Lalvani, operates a diversified consumer healthcare portfolio anchored by well-established brand franchises including Wellman and Wellwoman (targeted multivitamins), Perfectil (beauty-focused supplements), Pregnacare (prenatal vitamins), and Osteocare (bone health formulations). The company maintains significant geographic reach, with established operations in the United Kingdom, China, and India through its Meyer Vitabiotics subsidiary, which markets the Calcimax brand locally. The firm exports products to more than 100 countries and has received industry recognition, becoming the first vitamin company to receive the Queen's Award for Innovation in 2013.
The acquisition represents a strategic expansion of Bain Capital's consumer healthcare investments and capitalizes on secular growth trends in the global wellness market. According to sources, Bain has been exploring opportunities to introduce a co-investor to participate in the deal on a minority basis, though no final decision has been announced. The timing of the acquisition aligns with Bain Capital's recent strong fundraising cycle; the firm closed its Asia Fund VI at $10.5 billion in total capital in early 2026, surpassing its $7 billion target with approximately $9.1 billion in external commitments.
The Vitabiotics transaction is emblematic of intensifying dealmaking activity in the India-focused nutraceuticals and wellness space. Recent comparable transactions include USV Pharma's majority stake acquisition in Wellbeing Nutrition, HUL's purchase of the remaining stake in OZiva parent Zywie Ventures, and ongoing interest from major private equity platforms including Warburg Pincus and Goldman Sachs Private Equity in scaling wellness assets such as Universal NutriScience. The elevated M&A activity underscores institutional investor conviction in branded, export-oriented nutraceutical companies with established market positions and geographic diversification.
Vitabiotics, founded by Indian-origin entrepreneur Dr. Kartar Lalvani, operates a diversified consumer healthcare portfolio anchored by well-established brand franchises including Wellman and Wellwoman (targeted multivitamins), Perfectil (beauty-focused supplements), Pregnacare (prenatal vitamins), and Osteocare (bone health formulations). The company maintains significant geographic reach, with established operations in the United Kingdom, China, and India through its Meyer Vitabiotics subsidiary, which markets the Calcimax brand locally. The firm exports products to more than 100 countries and has received industry recognition, becoming the first vitamin company to receive the Queen's Award for Innovation in 2013.
The acquisition represents a strategic expansion of Bain Capital's consumer healthcare investments and capitalizes on secular growth trends in the global wellness market. According to sources, Bain has been exploring opportunities to introduce a co-investor to participate in the deal on a minority basis, though no final decision has been announced. The timing of the acquisition aligns with Bain Capital's recent strong fundraising cycle; the firm closed its Asia Fund VI at $10.5 billion in total capital in early 2026, surpassing its $7 billion target with approximately $9.1 billion in external commitments.
The Vitabiotics transaction is emblematic of intensifying dealmaking activity in the India-focused nutraceuticals and wellness space. Recent comparable transactions include USV Pharma's majority stake acquisition in Wellbeing Nutrition, HUL's purchase of the remaining stake in OZiva parent Zywie Ventures, and ongoing interest from major private equity platforms including Warburg Pincus and Goldman Sachs Private Equity in scaling wellness assets such as Universal NutriScience. The elevated M&A activity underscores institutional investor conviction in branded, export-oriented nutraceutical companies with established market positions and geographic diversification.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.